Identifying and definitional attributes | |
Metadata item type:![]() | Data Element |
---|---|
Short name:![]() | Castrate resistance indicator |
METEOR identifier:![]() | 492869 |
Registration status:![]() |
|
Definition:![]() | An indicator of whether a person with cancer has been found to have castrate resistance, as represented by a code. |
Data Element Concept: | Person with cancer—castrate resistance indicator |
Value domain attributes | |||||||
Representational attributes | |||||||
Representation class:![]() | Code | ||||||
---|---|---|---|---|---|---|---|
Data type:![]() | Boolean | ||||||
Format:![]() | N | ||||||
Maximum character length:![]() | 1 | ||||||
Permissible values:![]() |
| ||||||
Data element attributes | |||||||
Collection and usage attributes | |||||||
Guide for use:![]() | Record whether a person is classed as castrate resistant. Castrate resistance is indicated by two consecutive rising PSA levels being found in PSA tests that are at least two weeks apart despite castrate levels of testosterone (<50ng/dL). This element should be recorded in conjunction with Castrate resistance date. | ||||||
Source and reference attributes | |||||||
Submitting organisation:![]() | Cancer Australia | ||||||
Reference documents:![]() | National Comprehensive Cancer Network 2013. NCCN Guidelies in Oncology: Prostate Cancer Version 2.2013. National Comprehensive Cancer Network, Fort Washington Scher HI Halabi S Tannock I et al 2008. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 26: 1148-54 | ||||||
Relational attributes | |||||||
Related metadata references:![]() | See also Person with cancer—castrate resistance date, DDMMYYYY
| ||||||
Implementation in Data Set Specifications:![]() |
|